


Imrecoxib

Cat. No.:	HY-114200		
CAS No.:	395683-14-4		
Molecular Formula:	C ₂₁ H ₂₃ NO ₃ S		
Molecular Weight:	369.48		
Target:	COX		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (270.65 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.7065 mL	13.5325 mL	27.0651 mL
		5 mM	0.5413 mL	2.7065 mL	5.4130 mL
10 mM		0.2707 mL	1.3533 mL	2.7065 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC ₅₀ value of 18 nM, it also inhibits COX1- activity with an IC ₅₀ value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect ^[1] .	
IC ₅₀ & Target	Human COX-1 115 nM (IC ₅₀)	Human COX-2 18 nM (IC ₅₀)
In Vitro	Imrecoxib (BAP-909) (0.1-10 μM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCR ^[1]	

	Cell Line:	U937 cells
	Concentration:	0.1 μ M; 1 μ M; 10 μ M
	Incubation Time:	24 hours
	Result:	Decreased COX-2 mRNA level.
In Vivo	<p>Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours^[1].</p> <p>Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammatory polyarthritis^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Rat carrageenan-induced edema model ^[1]
	Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
	Administration:	Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection
	Result:	Inhibited the edema response with different doses.
	Animal Model:	Rat adjuvant-induced arthritis (AIA) model ^[1]
	Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
	Administration:	Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days
	Result:	Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg.

REFERENCES

[1]. Chen XH, et al. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004 Jul;25(7):927-31.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA